Literature DB >> 3237426

Human brain metabolism of morphine and naloxone.

Agneta Wahlström1, Bengt Winblad, Marie Bixo, Anders Rane.   

Abstract

The glucuronidation of morphine and naloxone was investigated in several regions of the human brain. Post-mortem brain tissue specimens were obtained from 19 patients 15 of whom had had cancer. With a few exceptions, all cancer patients had been treated with opiates during the terminal stage of their life. The glucuronide formation of morphine and naloxone was studied in vitro after incubation of the brain microsomal fraction with the substrate and uridine diphosphate glucuronic acid (UDPGA). The glucuronides were analyzed by high performance liquid chromatography. Glucuronidation of morphine and naloxone was catalyzed in 6 of the 19 investigated tissue specimens. The rate of formation of naloxone-3-glucuronide (N3G) exceeded that of the morphine-3-glucuronide (M3G). Morphine-6-glucuronide formation was found in only 2 specimens, in which the formation rate was 10% of the formation rate of M3G. When morphine and naloxone were present simultaneously at equal concentrations (3 mM), the N3G/M3G formation rate ratio increased compared to that when the 2 substrates were incubated one by one. Our findings are interesting from a clinical point of view since the pathways studied represent both bioactivation and inactivation steps in the metabolism of opioids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3237426     DOI: 10.1016/0304-3959(88)90219-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  13 in total

Review 1.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 2.  Clinical applications of commonly used contemporary antidotes. A US perspective.

Authors:  C A Bowden; E P Krenzelok
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

3.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

4.  Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans.

Authors:  Mark Wallace; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-07-19       Impact factor: 5.108

5.  Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study.

Authors:  M J Barjavel; J M Scherrmann; H N Bhargava
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 6.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide.

Authors:  Maarten Swartjes; René A G Mooren; Amanda R Waxman; Caroline Arout; Koen van de Wetering; Jan den Hartigh; Jos H Beijnen; Benjamin Kest; Albert Dahan
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

Review 8.  Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.

Authors:  G K Gourlay
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

9.  Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.

Authors:  R T van Dongen; B J Crul; P M Koopman-Kimenai; T B Vree
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

10.  Immobilization of microsomes into alginate beads is a convenient method for producing glucuronides from drugs.

Authors:  M Haumont; J Magdalou; J C Ziegler; R Bidault; J P Siest; G Siest
Journal:  Appl Microbiol Biotechnol       Date:  1991-07       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.